Exhibit 4.6






Exhibit 4.6




DEBENTURE AMENDMENT AGREEMENT



THIS AGREEMENT dated for reference December 22, 2005 is made



AMONG:



UOB CAPITAL INVESTMENTS PTE LTD

80 Raffles Place, UOB Plaza 2 #30-20 Singapore 048624



(the “Investor”)




OF THE FIRST PART



AND:



WEX PHARMACEUTICALS INC. (formerly known as INTERNATIONAL
WEX TECHNOLOGIES INC.), a corporation formed under the Canada
Business Corporations Act and having an office at 2100 –
1040 West Georgia Street, Vancouver, British Columbia V6E
4H1



(the “Company”)




OF THE SECOND PART



AND:



WEX MEDICAL LIMITED, a corporation formed under the laws of
Hong Kong and having an office at Unit A, 34/F., Manulife
Tower, 169 Electric Road, North Point, Hong Kong



(the “Subsidiary”)




OF THE THIRD PART



WHEREAS:





	A.	 	On June 14, 2004, the Investor advanced to the Subsidiary $1,500,000 (the “Advanced
Funds”) pursuant to a subscription agreement among the Investor, the Subsidiary and the
Company dated May 18, 2004 (the “Original Subscription Agreement”);

	 
	B.	 	Pursuant to the Original Subscription Agreement, the Subsidiary and the Company issued
to the Investor a debenture dated June 14, 2004 relating to the Advanced Funds (the
“Debenture”);





 


 









 






	C.	 	The Investor, the Subsidiary and the Company wish to enter into this Agreement to amend certain provisions of the Debenture as hereinafter provided; and

	 
	D.	 	Concurrently with the execution of this Agreement, the Investor, the Subsidiary and the
Company have agreed to amend the Original Subscription Agreement.





NOW THEREFORE in consideration of the mutual premises, covenants and agreements herein set forth,
and $1.00 now paid by each party to the others, and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto covenant and agree as
follows:





	1.	 	Definitions

	 
	 	 	In this Agreement and the recitals hereto, unless the context otherwise requires, any
capitalized term not otherwise defined herein will have the meaning ascribed thereto in the
Debenture.

	 
	2.	 	One Instrument

	 
	 	 	The parties hereto agree that the Debenture, as amended hereby, shall continue to have full
force and effect and this Agreement shall have effect, so far as practicable, as if all of
the provisions of the Debenture and this Agreement were contained in the one instrument.

	 
	3.	 	Amendments







	 	3.1	 	The definitions in section 1(l), (n) and (q) of the Debenture are deleted and
the following are substituted in their place:







	 	“(l) 	 	“Maturity Date” means December 31, 2007,”

	 
	 	“(n) 	 	“Subscription Agreement” means the subscription agreement among
the Investor, the Subsidiary and the Company dated May 18, 2004, as amended
December 22, 2005,”

	 
	 	“(q) 	 	“UOB Debentures” means this Debenture and the debentures issued
to each of UOB Venture (Shenzhen) Limited and UOB Venture Technology Investments
Ltd by the Companies and dated for reference June 14, 2004, each as amended
from time to time.”





 


 - 2 - 









 







	 	3.2	 	Article 3 of the Debenture is deleted and the following is substituted in its
place:

	 
	 	 	 	“THE ADVANCED FUNDS







	 	3.1	 	Repayment of the Advanced Funds

	 
	 	 	 	The Subsidiary promises to pay to the Investor the Advanced Funds
outstanding, less any amount already repaid by the Subsidiary to the Investor or converted into Common Shares in accordance with this Debenture, as follows
(the “Repayment Schedule”):










	 	(a)	 	$300,000 on or before December 31, 2005;

	 
	 	(b)	 	a further $112,500 on or before June 30, 2006;

	 
	 	(c)	 	a further $112,500 on or before September 30, 2006;

	 
	 	(d)	 	a further $225,000 on or before December 31, 2006;

	 
	 	(e)	 	a further $187,500 on or before March 31, 2007;

	 
	 	(f)	 	a further $187,500 on or before June 30, 2007;

	 
	 	(g)	 	a further $187,500 on or before September 30, 2007; and

	 
	 	(h)	 	a further $187,500 on or before December 31, 2007.







	 	 	 	Notwithstanding any other provision of this Debenture, in the event that the Subsidiary
fails to repay the Advanced Funds in accordance with the foregoing, the Company promises
to pay to the Investor on demand the Advanced Funds outstanding, less any amount already
repaid by the Subsidiary to the Investor or converted into Common Shares in accordance
with this Debenture, (together with accrued and unpaid interest).

	 
	 	3.2	 	Evidence of Advanced Funds

	 
	 	 	 	The indebtedness of the Subsidiary to the Investor in respect of the Advanced Funds
outstanding will be evidenced by this Debenture.

	 
	 	3.3	 	Interest

	 
	 	 	 	The Subsidiary will pay interest to the Investor both before as well as after default and
maturity on the Advanced Funds from the date of disbursement, at the rate of 5.5% per
annum calculated semi-annually not in advance and payable semi-annually. Interest will be
paid in United States currency.

	 
	 	3.4	 	Timing of Interest Payments

	 
	 	 	 	The first semi-annual interest payment will be due and payable on the first day of
October, 2004 and thereafter interest payments will be due and payable on the first day
of each April and October (unless that day is not a Business Day in which case the
payment will be made on the Business Day immediately preceding it) until all principal
and interest has been repaid in full. Any accrued and unpaid interest existing on the
Maturity Date shall be paid on the Maturity Date.





 


 - 3 - 









 






	 	3.5	 	Net Interest

	 
	 	 	 	It is intended that all payments of the Advanced Funds, interest and all
other monies required to be paid to the Investor pursuant to this Debenture
shall be made without deduction or withholding for any taxes. If under
applicable law the payor of any such amounts is required to deduct or
withhold any amount in respect of taxes, the Companies will gross-up the
amount of each such payment so that the Investor will be in the same
position had no amount in respect of taxes been withheld or deducted.”







	4.	 	Counterparts

	 
	 	 	This Agreement may be executed in any number of counterparts, each of which will be deemed
to be an original and all of which taken together will be deemed to constitute one and the
same instrument. Counterparts may be delivered either in original or faxed form and the
parties adopt any signatures received by a receiving fax machine as original signatures of
the parties; provided, however, that any party providing its signature in such manner will
promptly forward to the other party an original of the signed copy of this Agreement which
was so faxed.






IN WITNESS WHEREOF the parties hereto have duly executed this Agreement as of the day and year
first above written.



For and on behalf of

UOB CAPITAL INVESTMENTS PTE LTD




	 	 	 
	 /s/ “Terence Ong Sea Eng”
 

Signature

	 	 
	 
	 	 
	Terence Ong Sea Eng
 

Name

	 	 
	 
	 	 
	Authorized Signatory
 

Title

	 	 





 


 - 4 - 









 





	 	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	 	)	 	 	 
	BY WEX PHARMACEUTICALS INC.

	 	 	)	 	 	 
	in the presence of:

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	/s/ “Iain R. Mant”

	 	 	)	 	 	 
	 

Signature

	
)	 	 	 
	 

	 	 	)	 	 	/s/ “Edge Wang”
	 

	 	 	 	 	 	 
	Iain R. Mant

	 	 	)	 	 	EDGE WANG, PRESIDENT
	Barrister & Solicitor

	 	 	)	 	 	 
	 

Name

	
)	 	 	 
	 

	 	 	)	 	 	 
	2100 — 1075 West Georgia Street

	 	 	)	 	 	 
	Vancouver, BC V6E 3G2

	 	 	)	 	 	 
	604 631 4734

	 	 	)	 	 	 
	 

Address

	)	 	 	 
	 

	 	 	)	 	 	 
	 


	)	 	 	 
	 
	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	 	)	 	 	 
	BY WEX MEDICAL LIMITED

	 	 	)	 	 	 
	in the presence of:

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	/s/ “Iain R. Mant”

	 	 	)	 	 	 
	 

Signature

	
)	 	 	 
	 

	 	 	)	 	 	/s/ “Edge Wang”
	 

	 	 	 	 	 	 
	Iain R. Mant

	 	 	)	 	 	EDGE WANG, PRESIDENT
	Barrister & Solicitor

	 	 	)	 	 	 
	 

Name

	
)	 	 	 
	 

	 	 	)	 	 	 
	2100 — 1075 West Georgia Street

	 	 	)	 	 	 
	Vancouver, BC V6E 3G2

	 	 	)	 	 	 
	604 631 4734

	 	 	)	 	 	 
	 

Address

	
)	 	 	 
	 

	 	 	)	 	 	 
	 


	)	 	 	 







 


 - 5 - 












 




DEBENTURE AMENDMENT AGREEMENT



THIS AGREEMENT dated for reference December 22, 2005 is made



AMONG:



UOB VENTURE TECHNOLOGY INVESTMENTS LTD 
80 Raffles Place, UOB Plaza 2 #30-20, Singapore 048624



(the “Investor”)




OF THE FIRST PART



AND:



WEX PHARMACEUTICALS INC. (formerly known as
INTERNATIONAL WEX TECHNOLOGIES INC.), a corporation formed under
the Canada Business Corporations Act and having an office at
2100 — 1040 West Georgia Street, Vancouver, British Columbia V6E
4H1



(the “Company”)




OF THE SECOND PART



AND:



WEX MEDICAL LIMITED, a corporation formed under the laws of Hong
Kong and having an office at Unit A, 34/F., Manulife Tower, 169
Electric Road, North Point, Hong Kong



(the “Subsidiary”)




OF THE THIRD PART



WHEREAS:





	A.	 	On June 14, 2004, the Investor advanced to the Subsidiary $1,500,000 (the “Advanced
Funds”) pursuant to a subscription agreement among the Investor, the Subsidiary and the
Company dated May 18, 2004 (the “Original Subscription Agreement”);

	 
	B.	 	Pursuant to the Original Subscription Agreement, the Subsidiary and the Company issued
to the Investor a debenture dated June 14, 2004 relating to the Advanced Funds (the
“Debenture”);

	 
	C.	 	The Investor, the Subsidiary and the Company wish to enter into this Agreement to
amend certain provisions of the Debenture as hereinafter provided; and





 


 









 






	D.	 	Concurrently with the execution of this Agreement, the Investor, the Subsidiary
and the Company have agreed to amend the Original Subscription Agreement.





NOW THEREFORE in consideration of the mutual premises, covenants and agreements herein set forth,
and $1.00 now paid by each party to the others, and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto covenant and agree as
follows:





	1.	 	Definitions

	 
	 	 	In this Agreement and the recitals hereto, unless the context otherwise requires, any
capitalized term not otherwise defined herein will have the meaning ascribed thereto in the
Debenture.

	 
	2.	 	One Instrument

	 
	 	 	The parties hereto agree that the Debenture, as amended hereby, shall continue to have full
force and effect and this Agreement shall have effect, so far as practicable, as if all of
the provisions of the Debenture and this Agreement were contained in the one instrument.

	 
	3.	 	Amendments







	 	3.1	 	The definitions in section 1(l), (n) and (q) of the Debenture are deleted and
the following are substituted in their place:







	 	“(l)	 	“Maturity Date” means December 31, 2007,”

	 
	 	“(n)	 	 “Subscription Agreement” means the subscription agreement among
the Investor, the Subsidiary and the Company dated May 18, 2004, as amended
December 22, 2005,”

	 
	 	“(q)	 	 “UOB Debentures” means this Debenture and the debentures issued
to each of UOB Venture (Shenzhen) Limited and UOB Venture Technology
Investments Ltd by the Companies and dated for reference June 14, 2004, each
as amended from time to time.”







	 	3.2	 	Article 3 of the Debenture is deleted and the following is substituted in its
place:

	 
	 	 	 	 “THE ADVANCED FUNDS







	 	3.1	 	Repayment of the Advanced Funds


The Subsidiary promises to pay to the Investor the Advanced Funds
outstanding, less any amount already repaid by the Subsidiary to the
Investor or converted into Common Shares in accordance with this
Debenture, as follows (the “Repayment Schedule”):







	 	(a)	 	$300,000 on or before December 31, 2005;






 


 - 2 - 









 






	 	(b)	 	a further $112,500 on or before June 30, 2006;

	 
	 	(c)	 	a further $112,500 on or before September 30, 2006;

	 
	 	(d)	 	a further $225,000 on or before December 31, 2006;

	 
	 	(e)	 	a further $187,500 on or before March 31, 2007;

	 
	 	(f)	 	a further $187,500 on or before June 30, 2007;

	 
	 	(g)	 	a further $187,500 on or before September 30, 2007; and

	 
	 	(h)	 	a further $187,500 on or before December 31, 2007.







	 	 	 	Notwithstanding any other provision of this Debenture, in the event that the Subsidiary
fails to repay the Advanced Funds in accordance with the foregoing, the Company promises
to pay to the Investor on demand the Advanced Funds outstanding, less any amount already
repaid by the Subsidiary to the Investor or converted into Common Shares in accordance
with this Debenture, (together with accrued and unpaid interest).

	 
	 	3.2	 	Evidence of Advanced Funds

	 
	 	 	 	The indebtedness of the Subsidiary to the Investor in respect of the Advanced Funds
outstanding will be evidenced by this Debenture.

	 
	 	3.3	 	Interest

	 
	 	 	 	The Subsidiary will pay interest to the Investor both before as well as after default and
maturity on the Advanced Funds from the date of disbursement, at the rate of 5.5% per
annum calculated semi-annually not in advance and payable semi-annually. Interest will be
paid in United States currency.

	 
	 	3.4	 	Timing of Interest Payments

	 
	 	 	 	The first semi-annual interest payment will be due and payable on the first day of
October, 2004 and thereafter interest payments will be due and payable on the first day
of each April and October (unless that day is not a Business Day in which case the
payment will be made on the Business Day immediately preceding it) until all principal and
interest has been repaid in full. Any accrued and unpaid interest existing on the Maturity
Date shall be paid on the Maturity Date.





 


 - 3 - 









 






	 	3.5	 	Net Interest

	 
	 	 	 	It is intended that all payments of the Advanced Funds, interest and all
other monies required to be paid to the Investor pursuant to this Debenture
shall be made without deduction or withholding for any taxes. If under
applicable law the payor of any such amounts is required to deduct or
withhold any amount in respect of taxes, the Companies will gross-up the
amount of each such payment so that the Investor will be in the same
position had no amount in respect of taxes been withheld or deducted.”







	4.	 	Counterparts

	 
	 	 	This Agreement may be executed in any number of counterparts, each of which will be deemed
to be an original and all of which taken together will be deemed to constitute one and the
same instrument. Counterparts may be delivered either in original or faxed form and the
parties adopt any signatures received by a receiving fax machine as original signatures of
the parties; provided, however, that any party providing its signature in such manner will
promptly forward to the other party an original of the signed copy of this Agreement which
was so faxed.





IN WITNESS WHEREOF the parties hereto have duly executed this Agreement as of the day and year
first above written.




For and on behalf of

UOB VENTURE TECHNOLOGY

INVESTMENTS LTD




	 	 	 
	 /s/ “Seah Kian Wee”
 

Signature

	 	 
	 
	 	 
	Seah Kian Wee
 

Name

	 	 
	 
	 	 
	Managing Director of UOB Venture Management Pte Ltd.
 

Title

	 	 







 


 - 4 - 











 





	 	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	 	)	 	 	 
	BY WEX PHARMACEUTICALS INC.

	 	 	)	 	 	 
	in the presence of:

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	/s/ “Iain R. Mant”

	 	 	)	 	 	 
	 

Signature

	
)	 	 	 
	 

	 	 	)	 	 	/s/ “Edge Wang”
	 

	 	 	 	 	 	 
	Iain R. Mant

	 	 	)	 	 	EDGE WANG, PRESIDENT
	Barrister & Solicitor

	 	 	)	 	 	 
	 

Name

	
)	 	 	 
	 

	 	 	)	 	 	 
	2100 — 1075 West Georgia Street

	 	 	)	 	 	 
	Vancouver, BC V6E 3G2

	 	 	)	 	 	 
	604 631 4734

	 	 	)	 	 	 
	 

Address

	
)	 	 	 
	 

	 	 	)	 	 	 
	 


	)	 	 	 
	 
	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	 	)	 	 	 
	BY WEX MEDICAL LIMITED

	 	 	)	 	 	 
	in the presence of:

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	/s/ “Iain R. Mant”

	 	 	)	 	 	 
	 

Signature

	
)	 	 	 
	 

	 	 	)	 	 	/s/ “Edge Wang”
	 

	 	 	 	 	 	 
	Iain R. Mant

	 	 	)	 	 	EDGE WANG, PRESIDENT
	Barrister & Solicitor

	 	 	)	 	 	 
	 

Name

	
)	 	 	 
	 

	 	 	)	 	 	 
	2100 — 1075 West Georgia Street

	 	 	)	 	 	 
	Vancouver, BC V6E 3G2

	 	 	)	 	 	 
	604 631 4734

	 	 	)	 	 	 
	 

Address

	
)	 	 	 
	 

	 	 	)	 	 	 
	 


	)	 	 	 







 


 












 




DEBENTURE AMENDMENT AGREEMENT




THIS AGREEMENT dated for reference December 22, 2005 is made



AMONG:




UOB VENTURE (SHENZHEN) LIMITED

608, St James Court, St. Denis Street, Port Louis, Mauritius


(the “Investor”)



OF THE FIRST PART



AND:



WEX
PHARMACEUTICALS INC. (formerly known as INTERNATIONAL
WEX TECHNOLOGIES INC.), a corporation formed under the
Canada Business Corporations Act and having an office at
2100 — 1040 West Georgia Street, Vancouver, British Columbia
V6E 4H1




(the “Company”)



OF THE SECOND PART



AND:



WEX
MEDICAL LIMITED, a corporation formed under the laws of
Hong Kong and having an office at Unit A, 34/F., Manulife
Tower, 169 Electric Road, North Point, Hong Kong




(the “Subsidiary”)



OF THE THIRD PART




WHEREAS:




	A.	 	On June 14, 2004, the Investor advanced to the Subsidiary $2,100,000 (the “Advanced
Funds”) pursuant to a subscription agreement among the Investor, the Subsidiary and the
Company dated May 18, 2004 (the “Original Subscription Agreement”);

	 
	B.	 	Pursuant to the Original Subscription Agreement, the Subsidiary and the Company issued
to the Investor a debenture dated June 14, 2004 relating to the Advanced Funds (the
“Debenture”);





 


 









 





	C.	 	The Investor, the Subsidiary and the Company wish to enter into this Agreement to
amend certain provisions of the Debenture as hereinafter provided; and

	 
	D.	 	Concurrently with the execution of this Agreement, the Investor, the Subsidiary and the
Company have agreed to amend the Original Subscription Agreement.






NOW THEREFORE in consideration of the mutual premises, covenants and agreements herein set forth,
and $1.00 now paid by each party to the others, and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto covenant and agree as
follows:




	1.	 	Definitions

	 
	 	 	In this Agreement and the recitals hereto, unless the context otherwise requires, any
capitalized term not otherwise defined herein will have the meaning ascribed thereto in the
Debenture.

	 
	2.	 	One Instrument

	 
	 	 	The parties hereto agree that the Debenture, as amended hereby, shall continue to have full
force and effect and this Agreement shall have effect, so far as practicable, as if all of
the provisions of the Debenture and this Agreement were contained in the one instrument.

	 
	3.	 	Amendments







	 	3.1	 	The definitions in section 1(l), (n) and (q) of the Debenture are deleted and
the following are substituted in their place:







	 	“(l)	 	 “Maturity Date” means December 31, 2007,”

	 
	 	“(n)	 	“Subscription Agreement” means the subscription agreement among
the Investor, the Subsidiary and the Company dated May 18, 2004, as amended
December 22, 2005,”

	 
	 	“(q)	 	“UOB Debentures” means this Debenture and the debentures issued
to each of UOB Venture (Shenzhen) Limited and UOB Venture Technology
Investments Ltd by the Companies and dated for reference June 14, 2004, each
as amended from time to time.”







	 	3.2	 	Article 3 of the Debenture is deleted and the following is substituted in its
place:

	 
	 	 	 	“THE ADVANCED FUNDS





 


- 2 -









 











	 	3.1	 	Repayment of the Advanced Funds

	 
	 	 	 	The Subsidiary promises to pay to the Investor the Advanced Funds outstanding,
less any amount already repaid by the Subsidiary to the
Investor or converted into Common Shares in accordance with this Debenture, as follows (the
“Repayment Schedule”):







	 	(a)	 	$420,000 on or before December 31, 2005;

	 
	 	(b)	 	a further $ 157,500 on or before June 30, 2006;

	 
	 	(c)	 	a further $ 157,500 on or before September 30, 2006;

	 
	 	(d)	 	a further $315,000 on or before December 31, 2006;

	 
	 	(e)	 	a further $262,500 on or before March 31, 2007;

	 
	 	(f)	 	a further $262,500 on or before June 30, 2007;

	 
	 	(g)	 	a further $262,500 on or before September 30, 2007; and

	 
	 	(h)	 	a further $262,500 on or before December 31, 2007.







	 	 	 	Notwithstanding any other provision of this Debenture, in the event that the Subsidiary
fails to repay the Advanced Funds in accordance with the foregoing, the Company promises to
pay to the Investor on demand the Advanced Funds outstanding, less any amount already
repaid by the Subsidiary to the Investor or converted into Common Shares in accordance with
this Debenture, (together with accrued and unpaid interest).

	 
	 	3.2	 	Evidence of Advanced Funds

	 
	 	 	 	The indebtedness of the Subsidiary to the Investor in respect of the Advanced Funds
outstanding will be evidenced by this Debenture.

	 
	 	3.3	 	Interest

	 
	 	 	 	The Subsidiary will pay interest to the Investor both before as well as after default and
maturity on the Advanced Funds from the date of disbursement, at the rate of 5.5% per
annum calculated semi-annually not in advance and payable semi-annually. Interest will be
paid in United States currency.

	 
	 	3.4	 	Timing of Interest Payments

	 
	 	 	 	The first semi-annual interest payment will be due and payable on the first day of October,
2004 and thereafter interest payments will be due and payable on the first day of each
April and October (unless that day is not a Business Day in which case the payment will be
made on the Business Day immediately preceding it) until all principal and interest has
been repaid in full. Any accrued and unpaid interest existing on the Maturity Date shall be
paid on the Maturity Date.





 


- 3 -









 






	 	3.5	 	Net Interest

	 
	 	 	 	It is intended that all payments of the Advanced Funds, interest and all
other monies required to be paid to the Investor pursuant to this Debenture
shall be made without deduction or withholding for any taxes. If under
applicable law the payor of any such amounts is required to deduct or
withhold any amount in respect of taxes, the Companies will gross-up the
amount of each such payment so that the Investor will be in the same
position had no amount in respect of taxes been withheld or deducted.”







	4.	 	Counterparts

	 
	 	 	This Agreement may be executed in any number of counterparts, each of which will be deemed
to be an original and all of which taken together will be deemed to constitute one and the
same instrument. Counterparts may be delivered either in original or faxed form and the
parties adopt any signatures received by a receiving fax machine as original signatures of
the parties; provided, however, that any party providing its signature in such manner will
promptly forward to the other party an original of the signed copy of this Agreement which
was so faxed.






IN WITNESS WHEREOF the parties hereto have duly executed this Agreement as of the day and year
first above written.



For and on behalf of

UOB VENTURE (SHENZHEN) LIMITED




	 	 	 
	/s/ “Seah Kian Wee”
 

Signature

	 	 
	 
	 	 
	Seah Kian Wee
 

Name

	 	 
	 
	 	 
	Director of SZVC UOB Venture Management Co Ltd
 

Title

	 	 





 


- 4 -









 





	 	 	 	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	 	)	 	 	 	 	 
	BY
WEX PHARMACEUTICALS INC.

	 	 	)	 	 	 	 	 
	in the presence of:

	 	 	)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	 
	/s/ “Iain R. Mant”
 

Signature

	 	 	)

)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	/s/ “Edge Wang”
	 

	 	 	 	 	 	 	 	 
	Iain R. Mant

	 	 	)	 	 	 	 	EDGE WANG, PRESIDENT
	Barrister & Solicitor
 

Name

	 	 	)

)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	 
	2100 — 1075 West Georgia Street

	 	 	)	 	 	 	 	 
	Vancouver, BC V6E 3G2

	 	 	)	 	 	 	 	 
	604 631 4734
 

Address

	 	 	)

)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	 
	 


	 	 	)	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	 	)	 	 	 	 	 
	BY
WEX MEDICAL LIMITED

	 	 	)	 	 	 	 	 
	in the presence of:

	 	 	)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	 
	/s/ “Iain R. Mant”
 

Signature

	 	 	)

)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	/s/ “Edge Wang”
	 

	 	 	 	 	 	 	 	 
	Iain R. Mant

	 	 	)	 	 	 	 	EDGE WANG, PRESIDENT
	Barrister & Solicitor
 

Name

	 	 	)

)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	 
	2100 — 1075 West Georgia Street

	 	 	)	 	 	 	 	 
	Vancouver, BC V6E 3G2

	 	 	)	 	 	 	 	 
	604 631 4734
 

Address

	 	 	)

)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	 
	 

	 	 	)